Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Astellas
China - Shenyang
TACROLIMUS (tacrolimus) by Astellas is calcineurin inhibitors [moa]. Approved for organ rejection in adult patients receiving allogeneic liver, kidney, heart transplants and 3 more indications. First approved in 2023.
Drug data last refreshed 18h ago
Calcineurin Inhibitors
Calcineurin Inhibitor Immunosuppressant
Worked on TACROLIMUS at Astellas? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients
Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo